Funding & Investments Related News

These Fifty Synthetic Biology Companies Raised $1.7B in 2017

Given the record breaking amount of money going into synthetic biology companies, it seemed like 2016 was going to be hard for the industry to top. However, thanks to several late mega-raises from both public and private companies, 2017 is [...]

By | January 3rd, 2018|Funding & Investments, Synthetic Biology News|

Yield10 Bioscience Announces Closing of $14.5 Million Public Offering

WOBURN, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) today announced the closing of an underwritten public offering of units for gross proceeds of $14.5 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, [...]

Genetic Circuits Startup Asimov Raises Seed Round Led by Andreessen Horowitz

Funds Will Accelerate Development of Genetic Circuits Platform and Biotechnology Partnerships Cambridge, MA – December 19, 2017. Asimov, a startup using computer-aided design to engineer biology, announced today that it has raised $4.7 million in seed funding in a [...]

Leveraging the Power of Biology for Manufacturing: Ginkgo Bioworks Raises $275 Million in Series D Funding

Earlier today, Ginkgo Bioworks, the organism company, announced a new fundraising of $275 million from both existing and new investors. This money will be used to further their ability to genetically engineer novel organisms. For more information on what the [...]

Ginkgo Bioworks Launches New Organism Foundry, Supported by $275 Million in Series D Funding

As investors flock to synthetic biology, automated lab accelerates Ginkgo’s expansion to new markets Boston, Mass. – December 14 – Ginkgo Bioworks, the organism company, today announced the opening of Bioworks3 – Ginkgo’s third foundry for prototyping and scaling [...]

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Financing led by GV to focus on lead programs for next-generation oncology cell therapies Proprietary platform enables installation of pharmacologic operating systems in cell and gene therapy products to provide treating physicians with precise and dynamic control of engineered cells [...]